What changed in this filing

/stocks — the workspaceLOADING

Item 2. Unregistered Sales of Equity Securities

2021-11-09 compared with 2021-08-11 · 25 added, 15 removed, 5 unchanged (89% of the section changed)

Unregistered Sales of Equity Securities and Use of Proceeds

Use of Proceeds from Initial Public Offering of Common Stock

On September 22, 2017, we completed our initial public offering of 2,760,000 shares of our common stock at a price to the public of $9.50 per share.

The total number of shares of common stock sold in the offering includes the exercise of an overallotment we granted to Craig-Hallum Capital Group LLC, the sole managing underwriter of the offering, to purchase 360,000 shares of common stock.

The shares of common stock were registered for sale pursuant to Registration Statements on Form S-1 (Registration Nos.

333-220128 and 333-220527), filed with the SEC and declared effective on September 19, 2017 (the “Effective Date”).

The aggregate offering price for the registered shares of common stock was approximately $26.2 million.

The offering commenced on September 20, 2017 and did not terminate before all of the shares of common stock that were registered were sold.

The aggregate offering price for the shares of common stock sold in the offering was approximately $26.2 million.

We received net proceeds of approximately $23.3 million from the offering, after deducting underwriting discounts and commissions of approximately $1.8 million and offering expenses of approximately $1.1 million.

No payments for the foregoing expenses were made by us to any of our officers, directors or persons owning ten percent or more of our common stock, or to the associates of any of the foregoing, or to its affiliates, other than payments in the ordinary course of business to our officers for salaries and bonuses.

There has been no material change in the planned use of proceeds as described in our Prospectus filed with the SEC on September 20, 2017.

From the Effective Date through June 30, 2021, we have used approximately $17.5 million in furtherance of our planned use of proceeds, which includes funding additional research and development for discovery of new cancer sub-types and development and validation of new CELsignia tests;

of Proceeds from Initial Public Offering of Common Stock

September 22, 2017, we completed our initial public offering of 2,760,000 shares of our common stock at a price to the public of $9.50

The total number of shares of common stock sold in the offering includes the exercise of an overallotment we granted to Craig-Hallum

Capital Group LLC, the sole managing underwriter of the offering, to purchase 360,000 shares of common stock.

The shares of common stock

were registered for sale pursuant to Registration Statements on Form S-1 (Registration Nos.

333-220128 and 333-220527), filed with the

SEC and declared effective on September 19, 2017 (the “Effective Date”).

The aggregate offering price for the registered

shares of common stock was approximately $26.2 million.

The offering commenced on September 20, 2017 and did not terminate before all

of the shares of common stock that were registered were sold.

aggregate offering price for the shares of common stock sold in the offering was approximately $26.2 million.

We received net proceeds

of approximately $23.3 million from the offering, after deducting underwriting discounts and commissions of approximately $1.8 million

and offering expenses of approximately $1.1 million.

No payments for the foregoing expenses were made by us to any of our officers, directors

or persons owning ten percent or more of our common stock, or to the associates of any of the foregoing, or to its affiliates, other

than payments in the ordinary course of business to our officers for salaries and bonuses.

has been no material change in the planned use of proceeds as described in our Prospectus filed with the SEC on September 20, 2017.

the Effective Date through September 30, 2021, we have used approximately $21.5 million in furtherance of our planned use of proceeds,

which includes funding additional research and development for discovery of new cancer sub-types and development and validation of new

CELsignia tests;

clinical trials to support clinical claims;

development of operational processes and capital expenditures;

and working capital and other general corporate purposes.

Recent Unregistered Sales of Equity Securities

capital and other general corporate purposes.

Unregistered Sales of Equity Securities

Defaults Upon Senior Securities

Mine Safety Disclosures

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Unregistered Sales of Equity Securities